Research - Acetyl-L-Carnitine / L-Carnitine
__
L-Carnitine Improves the Asthma Control in Children with Moderate Persistent Asthma
Mohammed Al-Biltagi,1 Mona Isa,2 Adel Salah Bediwy,3 Nevien Helaly,2 and Dalia D. El Lebedy4
1Department of Paediatric, Faculty of Medicine, Tanta University, Tanta, P.o. box 1084, Gharbia Governate, Egypt
2Department of Paediatric, Abu Alrish Pediatric Hospital, Faculty of Medicine, Cairo University, Cairo, Egypt
3Department of Chest Diseases, Faculty of Medicine, Tanta University, Tanta, Gharbia Governate, Egypt
4Department of Clinical and Chemical Pathology, Medical Division, National Research Center, Cairo, Egypt
Abstract
The objective. was to investigate L-Carnitine level and the effects of its supplementation in children with moderate persistent Asthma. Methods. Free and total serum carnitine levels were measured in 50 children having moderate persistent asthma and 50 healthy control children. The patients group was randomly divided into two subgroups. Subgroup A was supplemented with L-carnitine for 6 months while subgroup B was used as a placebo controls. Both subgroups were assessed by pulmonary function tests (PFT) and childhood-asthma control test (C-ACT) before and 6 months after carnitine supplementation. Results. Total and free carnitine levels were significantly lower in patient group than in control group. PFT and C-ACT showed significant improvements in asthmatic children supplemented with L-carnitine than in those who were not supplemented. Conclusion. L-carnitine levels were initially lower in moderate persistent asthmatic children as compared to healthy control children. Asthmatic children who received L-carnitine supplementation showed statistically significant improvement of C-ACT and PFT.
Source : Journal of Allergy Volume 2012 (2012), Article ID 509730, 7 pages doi:10.1155/2012/509730
Link to Full Article
Acetyl-L-carnitine (carnicetine) in the treatment of early stages of Alzheimer's disease and vascular dementia].
Abstract
Efficacy, safety and tolerability of acetyl-L-carnitine (ALC) were studied during the double-blind placebo-controlled 12-week trial in patients with mild (initial) dementia caused by the Alzheimer's disease (AD) and vascular dementia (VD). ALC was administered in doses from 2250 to 3000 mg per day. Patient's state was assessed with some scales (MMSE, CGI etc) and a battery of neuropsychological tests. The treatment effect of ALC was 2,8 times higher than in placebo-treated patients. The clinical improvement by CGI scores was significantly better in AD patients compared to VD and did not depend on the severity of baseline cognitive deficit. The drug was well-tolerated. Carnicetine can be recommended in the abovementioned doses for treatment of early stages of AD and VD.
Source : Pubmed via Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(9):16-22.
Link to Abstract
L-Carnitine Improves the Asthma Control in Children with Moderate Persistent Asthma
Mohammed Al-Biltagi,1 Mona Isa,2 Adel Salah Bediwy,3 Nevien Helaly,2 and Dalia D. El Lebedy4
1Department of Paediatric, Faculty of Medicine, Tanta University, Tanta, P.o. box 1084, Gharbia Governate, Egypt
2Department of Paediatric, Abu Alrish Pediatric Hospital, Faculty of Medicine, Cairo University, Cairo, Egypt
3Department of Chest Diseases, Faculty of Medicine, Tanta University, Tanta, Gharbia Governate, Egypt
4Department of Clinical and Chemical Pathology, Medical Division, National Research Center, Cairo, Egypt
Abstract
The objective. was to investigate L-Carnitine level and the effects of its supplementation in children with moderate persistent Asthma. Methods. Free and total serum carnitine levels were measured in 50 children having moderate persistent asthma and 50 healthy control children. The patients group was randomly divided into two subgroups. Subgroup A was supplemented with L-carnitine for 6 months while subgroup B was used as a placebo controls. Both subgroups were assessed by pulmonary function tests (PFT) and childhood-asthma control test (C-ACT) before and 6 months after carnitine supplementation. Results. Total and free carnitine levels were significantly lower in patient group than in control group. PFT and C-ACT showed significant improvements in asthmatic children supplemented with L-carnitine than in those who were not supplemented. Conclusion. L-carnitine levels were initially lower in moderate persistent asthmatic children as compared to healthy control children. Asthmatic children who received L-carnitine supplementation showed statistically significant improvement of C-ACT and PFT.
Source : Journal of Allergy Volume 2012 (2012), Article ID 509730, 7 pages doi:10.1155/2012/509730
Link to Full Article
Acetyl-L-carnitine (carnicetine) in the treatment of early stages of Alzheimer's disease and vascular dementia].
Abstract
Efficacy, safety and tolerability of acetyl-L-carnitine (ALC) were studied during the double-blind placebo-controlled 12-week trial in patients with mild (initial) dementia caused by the Alzheimer's disease (AD) and vascular dementia (VD). ALC was administered in doses from 2250 to 3000 mg per day. Patient's state was assessed with some scales (MMSE, CGI etc) and a battery of neuropsychological tests. The treatment effect of ALC was 2,8 times higher than in placebo-treated patients. The clinical improvement by CGI scores was significantly better in AD patients compared to VD and did not depend on the severity of baseline cognitive deficit. The drug was well-tolerated. Carnicetine can be recommended in the abovementioned doses for treatment of early stages of AD and VD.
Source : Pubmed via Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(9):16-22.
Link to Abstract